133 related articles for article (PubMed ID: 38124404)
1. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial.
de la Espriella R; Wahlberg KJ; Infeld M; Palau P; Núñez E; Sanchis J; Meyer M; Núñez J
Eur J Heart Fail; 2024 Jan; 26(1):167-176. PubMed ID: 38124404
[TBL] [Abstract][Full Text] [Related]
2. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.
Infeld M; Wahlberg K; Cicero J; Plante TB; Meagher S; Novelli A; Habel N; Krishnan AM; Silverman DN; LeWinter MM; Lustgarten DL; Meyer M
JAMA Cardiol; 2023 Mar; 8(3):213-221. PubMed ID: 36723919
[TBL] [Abstract][Full Text] [Related]
3. Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial.
Wahlberg KJ; Infeld M; Plante TB; Novelli AE; Habel N; Burkhoff D; Barrett T; Lustgarten D; Meyer M
J Am Heart Assoc; 2024 Jan; 13(1):e032873. PubMed ID: 38156545
[TBL] [Abstract][Full Text] [Related]
4. Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: Design and rationale for the
Infeld M; Wahlberg K; Cicero J; Meagher S; Habel N; Muthu Krishnan A; Silverman DN; Lustgarten DL; Meyer M
Heart Rhythm O2; 2022 Feb; 3(1):109-116. PubMed ID: 35243443
[TBL] [Abstract][Full Text] [Related]
5. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
[TBL] [Abstract][Full Text] [Related]
6. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
7. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).
Patel RB; Vaduganathan M; Felker GM; Butler J; Redfield MM; Shah SJ
Am J Cardiol; 2019 May; 123(10):1660-1666. PubMed ID: 30876658
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study.
Linde C; Ekström M; Eriksson MJ; Maret E; Wallén H; Lyngå P; Wedén U; Cabrera C; Löfström U; Stenudd J; Lund LH; Persson B; Persson H; Hage C;
ESC Heart Fail; 2022 Aug; 9(4):2125-2138. PubMed ID: 35403374
[TBL] [Abstract][Full Text] [Related]
9. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
11. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
13. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
14. Effects of a Higher Heart Rate on Quality of Life and Functional Capacity in Patients With Left Ventricular Diastolic Dysfunction.
Wahlberg K; Arnold ME; Lustgarten D; Meyer M
Am J Cardiol; 2019 Oct; 124(7):1069-1075. PubMed ID: 31395299
[TBL] [Abstract][Full Text] [Related]
15. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
16. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
17. Correlates of Plasma NT-proBNP/Cyclic GMP Ratio in Heart Failure With Preserved Ejection Fraction: An Analysis of the RELAX Trial.
Chiu L; Agrawal V; Armstrong D; Brittain E; Collins S; Hemnes AR; Hill JA; Lindenfeld J; Shah SJ; Stevenson LW; Wang TJ; Gupta DK
J Am Heart Assoc; 2024 Apr; 13(7):e031796. PubMed ID: 38533961
[TBL] [Abstract][Full Text] [Related]
18. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
[TBL] [Abstract][Full Text] [Related]
19. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy.
Kaufmann BA; Goetschalckx K; Min SY; Maeder MT; Bucher U; Nietlispach F; Bernheim AM; Pfisterer ME; Brunner-La Rocca HP;
Int J Cardiol; 2015 Jul; 191():286-93. PubMed ID: 25981371
[TBL] [Abstract][Full Text] [Related]
20. Heart failure with preserved ejection fraction, atrial fibrillation, and increased NT‑proBNP levels : An emergent clinical dilemma.
Turkoglu EI; Kircicegi Cicekdag EC
Herz; 2021 Sep; 46(Suppl 2):191-197. PubMed ID: 32997152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
